A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment

Wen Tsung Huang, Hong Hwa Chen, Chung Hung Yeh, Yin Che Lu, Wei Shou Hwang, Jen Seng Huang, Chou Pin Chen, Peng Chan Lin, Wu Ching Uen, Yang Cheng Lee, Hwei Ming Wang, Hong Cheng Wu, Jinn Shiun Chen, Ruey Ho Kao, Chi Chou Huang, Hao Hsuan Jeng, Chia Jung Lin, Ruey Kuen Hsieh